Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Repare Therapeutics Inc. - Common Shares (RPTX)
Company Research
Source: Business Wire
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced a Cooperative Research and Development Agreement (CRADA) has been executed to advance the development of camonsertib as an anticancer agent in collaboration with the Cancer Therapy Evaluation Program (CTEP) of the US National Cancer Institute (NCI), part of the US National Institutes of Health.“This partnership with the CTEP allows the research community to investigate the full clinical potential of camonsertib more easily and we believe it will provide additional clinical development catalysts for the program,” said Lloyd M. Segal, President and Chief Executive Officer of Repare.Camonsertib, a potential best-in-class oral small molecule ATR inhibitor, has demonstrated significant anti-tumor activity in preclinical and clinical studies. Ongoing clinical trials in patients with metastatic solid tumors
Show less
Read more
Impact Snapshot
Event Time:
RPTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPTX alerts
High impacting Repare Therapeutics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
RPTX
News
- Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib [Yahoo! Finance]Yahoo! Finance
- Repare Therapeutics Inc. (NASDAQ: RPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial ResultsBusiness Wire
- Repare Therapeutics Inc. (NASDAQ: RPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
RPTX
Earnings
- 2/28/24 - Miss
RPTX
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- RPTX's page on the SEC website